All Stories

  1. Model-based analysis of thromboxane B2 and prostaglandin E2 as biomarkers in the safety evaluation of naproxen
  2. Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research
  3. A model‐based approach for the evaluation of once daily dosing of lamivudine in HIV‐infected children
  4. Covariate effects and population pharmacokinetics of lamivudine in HIV‐infected children
  5. Integrative knowledge management to enhance pharmaceutical R&D
  6. Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs
  7. Not‐in‐trial simulation I: Bridging cardiovascular risk from clinical trials to real‐life conditions
  8. Identifying the translational gap in the evaluation of drug‐induced QTc interval prolongation
  9. Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain
  10. Cardiovascular Disease: The Other Face of Diabetes
  11. Analysis of Oxcarbazepine and the 10‐Hydroxycarbazepine Enantiomers in Plasma by LC‐MS/MS: Application in a Pharmacokinetic Study
  12. Translational pharmacology: from animal to man and back
  13. Oc020—Optimal Sampling Strategy For Busulfan In Stem Cell Transplantation Patients
  14. PP012—Not-in-trial simulations: Predicting cardiovascular risk from clinical trials to real life conditions
  15. PP191—Influence of Verapamil on the Pharmacokinetics of Oxcarbazepine and 10-Hydroxycarbazepine Enantiomers in Healthy Volunteers
  16. PP209—Model-Based Analysis of the Pharmacokinetics of a Modified Release Formulation af Paracetamol After Twice Daily Dosing and Potential Implications for the Risk of Hepatotoxicity in Osteoarthritis Patients
  17. Population pharmacokinetics of abacavir in infants, toddlers and children
  18. White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation
  19. Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations
  20. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans
  21. Optimised protocol design for the screening of analgesic compounds in neuropathic pain
  22. Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain
  23. Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models
  24. Translation of drug effects from experimental models of neuropathic pain and analgesia to humans
  25. Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children
  26. Feasibility of a Fixed-Dose Regimen of Pyrazinamide and Its Impact on Systemic Drug Exposure and Liver Safety in Patients with Tuberculosis
  27. Assessment Of COPD Exacerbations Using A Bayesian Two-State Mixed Model
  28. Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases
  29. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV‐infected infants and toddlers
  30. Bridging Strategies for Drug Combinations in Pediatric Indications
  31. Changes in Research and Development of Medicinal Products since the Paediatric Regulation
  32. Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Clinical Drug Development
  33. Modelling of the outcome of non-inferiority trials by integration of historical data
  34. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?
  35. Translation of drug-induced QTc prolongation in early drug development
  36. Optimising first-in-human (FIH) dosing decisions
  37. The Pharmacokinetics and Pharmacological Effect of (S)-5-OH-DPAT Following Controlled Delivery with Transdermal Iontophoresis
  38. From Trial and Error to Trial Simulation III: A Framework for Interim Analysis in Efficacy Trials With Antidepressant Drugs
  39. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
  40. Modelling and simulation as research tools in paediatric drug development
  41. Development of Paediatric Medicines: Concepts and Principles
  42. PKPD and Disease Modeling: Concepts and Applications to Oncology
  43. Disease Progression Analysis: Towards Mechanism-Based Models
  44. What is the right dose for children?
  45. The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery
  46. The missing link between clinical endpoints and drug targets in depression
  47. Impact of chronic inflammation on the pharmacokinetic–pharmacodynamic relationship of naproxen
  48. A Model-Based Approach to Dose Selection in Early Pediatric Development
  49. Guide through the EMA Paediatric Website
  50. Paediatric Homework: Paediatric Investigation Plan Key Elements
  51. Study and Protocol Design for Paediatric Patients of Different Ages
  52. Value of probabilistic concentration–response modeling in cardiac safety
  53. From Trial and Error to Trial Simulation. Part 2: An Appraisal of Current Beliefs in the Design and Analysis of Clinical Trials for Antidepressant Drugs
  54. From Trial and Error to Trial Simulation. Part 1: The Importance of Model-Based Drug Development for Antidepressant Drugs
  55. Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy
  56. Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations
  57. Analysis of the Relationship Between Age and Treatment Response in Migraine
  58. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo‐oxygenase inhibitors
  59. The Task-force in Europe for Drug Development for the Young (TEDDY) Network of Excellence
  60. Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with ‘what-ifs’
  61. Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain
  62. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model
  63. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy
  64. Parallel, distributed and network-based processing
  65. Prediction of Attack Frequency in Migraine Treatment
  66. Efficacy of pulmonary insulin delivery in diabetic rats: Use of a model-based approach in the evaluation of insulin powder formulations
  67. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats
  68. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats
  69. Relevance of Absorption Rate and Lag Time to??the Onset of Action in Migraine
  70. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations
  71. Analysis of responses in migraine modelling using hidden Markov models
  72. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution, Receptor Theory, and Dynamical Systems Analysis
  73. Markers of exacerbation severity in chronic obstructive pulmonary disease
  74. Pharmacokinetics and Pharmacodynamics Analysis of Transdermal Iontophoresis of 5-OH-DPAT in Rats: In vitro–in vivo Correlation
  75. Markers of disease severity in chronic obstructive pulmonary disease
  76. Correlation between in vitro and in vivo concentration–effect relationships of naproxen in rats and healthy volunteers
  77. A model‐based approach to treatment comparison in acute migraine
  78. Prediction of Headache Response in Migraine Treatment
  79. Study and Protocol Design for Paediatric Patients of Different Ages
  80. Compartmental Modeling of Transdermal Iontophoretic Transport II: In Vivo Model Derivation and Application
  81. Pharmacokinetic pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors
  82. Compartmental Modeling of Transdermal Iontophoretic Transport: I. In Vitro Model Derivation and Application
  83. Population pharmacokinetic–pharmacodynamic modelling of S 15535, a 5-HT1A receptor agonist, using a behavioural model in rats
  84. Pharmacokinetic‐pharmacodynamic modelling in the early development phase of anti‐psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats
  85. Pharmacokinetic–pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model
  86. Pharmacokinetic–pharmacodynamic modelling of behavioural responses